Mersana Therapeutics, Inc.
MRSN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $56 | $77 | $102 | $108 |
| Short-Term Investments | $0 | $0 | $0 | $27 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $3 | $4 | $2 |
| Total Curr. Assets | $60 | $80 | $106 | $137 |
| Property Plant & Equip (Net) | $2 | $4 | $6 | $7 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $1 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $0 | $1 |
| Total NC Assets | $3 | $4 | $6 | $8 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $63 | $85 | $112 | $145 |
| Liabilities | – | – | – | – |
| Payables | $2 | $3 | $4 | $4 |
| Short-Term Debt | $2 | $21 | $16 | $16 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $24 | $20 | $24 | $22 |
| Other Curr. Liab. | $15 | $16 | $14 | $20 |
| Total Curr. Liab. | $43 | $59 | $58 | $62 |
| LT Debt | $0 | $0 | $8 | $12 |
| Deferred Rev, NC | $0 | $78 | $77 | $79 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $79 | $0 | $0 | $0 |
| Total NC Liab. | $79 | $78 | $85 | $92 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $3 | $4 | $5 |
| Total Liabilities | $122 | $138 | $143 | $154 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$952 | -$944 | -$920 | -$896 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $892 | $891 | $889 | $886 |
| Total Equity | -$60 | -$53 | -$31 | -$10 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $63 | $85 | $112 | $145 |
| Net Debt | -$54 | -$56 | -$78 | -$79 |